CHAPTER 1 INTRODUCTION

1.1. REPORT DESCRIPTION
1.2. KEY BENEFITS FOR STAKEHOLDERS
1.3. KEY MARKET SEGMENTS
1.4. RESEARCH METHODOLOGY

1.4.1. Secondary research
1.4.2. Primary research
1.4.3. Analyst tools and models

CHAPTER 2 EXECUTIVE SUMMARY

2.1. KEY FINDINGS OF THE STUDY
2.2. CXO PERSPECTIVE

CHAPTER 3 MARKET OVERVIEW

3.1. MARKET DEFINITION AND SCOPE
3.2. KEY FINDINGS

3.2.1. Top winning strategies
3.2.2. Top investment pockets

3.3. MARKET SHARE ANALYSIS, 2016
3.4. MARKET DYNAMICS

3.4.1. Drivers
3.4.2. Restraints
3.4.3. Opportunities
3.4.4. Impact analysis

CHAPTER 4 GLOBAL IDIOPATHIC PULMONARY FIBROSIS MARKET, BY DRUG TYPE

4.1. OVERVIEW

4.1.1. Market size and forecast

4.2. PIRFENIDONE

4.2.1. Key market trends
4.2.2. Growth factors and opportunities
4.2.3. Market size and forecast

4.3. NINTEDANIB

4.3.1. Key market trends
4.3.2. Growth factors and opportunities
4.3.3. Market size and forecast

CHAPTER 5 IDIOPATHIC PULMONARY FIBROSIS MARKET, BY REGION

5.1. OVERVIEW

5.1.1. Market size and forecast

5.2. NORTH AMERICA

5.2.1. Key market trends
5.2.2. Key growth factors and opportunities
5.2.3. Market size and forecast
5.2.4. U.S.
5.2.5. Canada
5.2.6. Mexico

5.3. EUROPE

5.3.1. Key market trends
5.3.2. Key growth factors and opportunities
5.3.3. Market size and forecast
5.3.4. Germany
5.3.5. France
5.3.6. UK
5.3.7. Italy
5.3.8. Spain
5.3.9. Rest of Europe

5.4. ASIA-PACFIC

5.4.1. Key market trends
5.4.2. Key growth factors and opportunities
5.4.3. Market size and forecast
5.4.4. Japan
5.4.5. China
5.4.6. India
5.4.7. South Korea
5.4.8. Rest of Asia-Pacific

5.5. LAMEA

5.5.1. Key market trends
5.5.2. Key growth factors and opportunities
5.5.3. Market size and forecast
5.5.4. Brazil
5.5.5. South Africa
5.5.6. Saudi Arabia
5.5.7. Rest of LAMEA

CHAPTER 6 COMPANY PROFILES

6.1. MEDICINOVA, INC.

6.1.1. Company overview
6.1.2. Operating business segments
6.1.3. Business performance
6.1.4. Key strategic moves and developments

6.2. BOEHRINGER INGELHEIM

6.2.1. Company overview
6.2.2. Operating business segments
6.2.3. Business performance
6.2.4. Key strategic moves and developments

6.3. F. HOFFMANN-LA ROCHE

6.3.1. Company overview
6.3.2. Operating business segments
6.3.3. Business performance
6.3.4. Key strategic moves and developments

6.4. FIBROGEN, INC.

6.4.1. Company overview
6.4.2. Operating business segments
6.4.3. Business performance
6.4.4. Key strategic moves and developments

6.5. PROMEDIOR, INC.

6.5.1. Company overview
6.5.2. Operating business segments
6.5.3. Business performance
6.5.4. Key strategic moves and developments

6.6. MERCK & CO., INC.

6.6.1. Company overview
6.6.2. Operating business segments
6.6.3. Business performance
6.6.4. Key strategic moves and developments

6.7. GALAPAGOS NV

6.7.1. Company overview
6.7.2. Operating business segments
6.7.3. Business performance
6.7.4. Key strategic moves and developments

6.8. BIOGEN

6.8.1. Company overview
6.8.2. Operating business segments
6.8.3. Business performance
6.8.4. Key strategic moves and developments

6.9. BRISTOL-MYERS SQUIBB COMPANY

6.9.1. Company overview
6.9.2. Operating business segments
6.9.3. Business performance
6.9.4. Key strategic moves and developments

6.10. PROMETIC LIFE SCIENCES INC.

6.10.1. Company overview
6.10.2. Operating business segments
6.10.3. Business performance
6.10.4. Key strategic moves and developments

6.11. CIPLA INC.

6.11.1. Company overview
6.11.2. Operating business segments
6.11.3. Business performance
6.11.4. Key strategic moves and developments